Tisagenlecleucel CD19 CAR-T for R/R B-ALL ≤25 years
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | None declared |
|---|
| ID | REG-TISAGENLECLEUCEL-B-ALL |
|---|---|
| Type | Regimen |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-ELIANA-MAUDE-2018 SRC-NCCN-BCELL-2025 |
Notes
CD19 CAR-T (4-1BB costimulation) for R/R B-ALL ages ≤25. ELIANA: ORR 81%, CR/CRi 60%, 12-mo EFS 50%, OS 76%. Single curative-intent infusion. CRS + ICANS boxed warnings — REMS/FACT-JACIE-accredited center mandatory. Bridging chemo during manufacturing window. Adult B-ALL (>25) — brexucabtagene autoleucel (Tecartus) is the registered alternative (separate Regimen entity, future). STUB — pending Co-Lead sign-off.
Used By
Indication
IND-B-ALL-3L-TISAGENLECLEUCEL- IND-B-ALL-3L-TISAGENLECLEUCEL